Fig. 2
From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Brain MRI of a representative study participant at baseline, showing axial, T1-weighted, post-gadolinium (a) and T2-FLAIR (b) images. Brain MRI of the same participant after 10 months of protocol therapy, showing axial, T1-weighted, post-gadolinium (c) and T2-FLAIR (d) images, consistent with response to treatment
